Metabolic Tumor Heterogeneity Hints at NSCLC PrognosisMetabolic Tumor Heterogeneity Hints at NSCLC Prognosis
Can glucose metabolic heterogeneity signal prognosis in non-small cell lung cancer (NSCLC) patients treated with erlotinib? Medscape Radiology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 15, 2015 Category: Radiology Tags: Radiology Viewpoint Source Type: news
Erlotinib cost effective for NSCLC in the US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2015 Category: Drugs & Pharmacology Source Type: news
erlotinib, Tarceva
Title: erlotinib, TarcevaCategory: MedicationsCreated: 11/28/2004 12:00:00 AMLast Editorial Review: 7/21/2015 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 21, 2015 Category: Cancer & Oncology Source Type: news
Erlotinib therapy based on EGFR mutation status cost effective
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2015 Category: Drugs & Pharmacology Source Type: news
[Research Article] Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
Triple antibody targeting of multiple receptors subverts the resistance induced by single-agent therapies in lung cancer. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - June 1, 2015 Category: Science Authors: Maicol Mancini, Nadège Gaborit, Moshit Lindzen, Tomer Meir Salame, Massimiliano Dall'Ora, Michal Sevilla-Sharon, Ali Abdul-Hai, Julian Downward, Yosef Yarden Source Type: news
Kidney cancer patients respond well to a combination of 2 existing anti-cancer drugs
(ECCO-the European CanCer Organisation) Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs. The 26th EORTC-NCI-AACR Symposium will hear that the combination of bevacizumab and erlotinib produced excellent response rates in patients with advanced papillary renal cell carcinoma (pRCC) and in patients with a highly aggressive form of pRCC called hereditary leiomyomatosis and renal cell cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 18, 2014 Category: Cancer & Oncology Source Type: news
Why targeted drug doesn't benefit patients with early-stage lung cancer
This study might explain why. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 27, 2014 Category: Science Source Type: news
Study may explain why targeted drug doesn't benefit patients with early-stage lung cancer
This study might explain why. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 27, 2014 Category: Cancer & Oncology Source Type: news
PET Imaging for Tyrosine Kinase Inhibitor (TKI) Biodistribution in Mice
Receptor tyrosine kinases play a critical role in cell growth, survival, and proliferation, and are considered potential molecular targets for the treatment of cancer. Although several tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, have demonstrated clinical efficacy via the inhibition of the epidermal growth factor receptor (EGFR), most TKIs are only effective in a small proportion of patients. Positron emission tomography (PET) imaging is a methodology of molecular imaging based on nuclear imaging. PET imaging in combination with radiolabeled TKIs improves accuracy of quantitative imaging strategies ...
Source: Springer protocols feed by Cancer Research - October 15, 2014 Category: Cancer & Oncology Source Type: news
Roche and Cipla enter talks to settle Erlotinib patent row
The development comes after a division bench of the Delhi HC referred the companies to a mediation that both firms chose to accept. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 12, 2014 Category: Pharmaceuticals Source Type: news
Hoffman La Roche and Cipla enters talks with Erlotinib to settle patent row
The development comes after a division bench of the Delhi HC referred the companies to a mediation that both firms chose to accept. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 12, 2014 Category: Pharmaceuticals Source Type: news
Josh Schafer, MSc. MBA
Vice President, Oncology Global Marketing StrategyJoshua Schafer is Vice President, Oncology Global Marketing Strategy at Astellas Pharmaceuticals, which a global top 20 pharmaceutical company. In his current role Mr. Schafer is responsible for global strategy and commercial leadership for Astellas Pharmaceuticals’ oncology portfolio with revenues of approximately $1.5B. Most recently he led the global launch of Xtandi for prostate cancer. He is a member of the Oncology Leadership team responsible for long term strategic planning, portfolio asset prioritization, development planning, and investment decisions includ...
Source: PHRMA - June 5, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
The combination of Roche's Avastin and Tarceva helped people with a specific form of lung cancer live longer without their disease worsening
Phase II study in Japanese patients with a specific type of lung cancer meets primary endpoint of improved progression-free survival with the combination of Avastin and Tarceva compared to Tarceva alone. Roche today announced results from the phase II JO25567 study in which Avastin® (bevacizumab) was added to Tarceva® (erlotinib) as initial (first-line) treatment for people with advanced non-small cell lung cancer (NSCLC) characterised by activating mutations of the epidermal growth factor receptor (EGFR Mut+). Patients who received the combination in this study lived significantly longer without their disease ge...
Source: Roche Investor Update - June 2, 2014 Category: Pharmaceuticals Source Type: news
Genprex starts patient enrolment in Phase II trial of lung cancer drug
US-based biopharmaceutical firm Genprex has started enrolling patients in a Phase II clinical trial evaluating its lead product candidate Oncoprex in combination with erlotinib (Tarceva) to treat late-stage lung cancer patients. (Source: Drug Development Technology)
Source: Drug Development Technology - May 20, 2014 Category: Pharmaceuticals Source Type: news
Phase II trial of efatutazone shows challenge of matching treatment to population
(University of Colorado Denver) Work at the University of Colorado Cancer Center led to phase II trial of efatutazone with erlotinib in patients with refractory non-small cell lung cancer. Results are reported today at the American Association for Cancer Research Annual Meeting 2014. While efatutazone did not improve the efficacy of erlotinib in this trial, researchers hope lessons from the trial will allow them to make better future use of the drug or other drugs in its class. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 8, 2014 Category: Cancer & Oncology Source Type: news
